证券代码：600252 证券简称：中恒集团 公告编号：临 2023-49 广西梧州中恒集团股份有限公司 关于控股孙公司获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 获得补助金额：41,593,315.00 元 ● 对当期损益的影响：本次收到政府补助共 41,593,315.00 元，其中，2022 年计提 29,999,330.93 元，已计入 2022 年度当期损益其他收益科目，2022 年计提 金额与实际收到金额之间的差额 11,593,984.07 元将计入 2023 年度当期损益。 一、获取政府补助的基本情况 广西梧州中恒集团股份有限公司（以下简称"公司"）控股孙公司西藏莱美 德济医药有限公司（以下简称"莱美德济"）依据《拉萨经济技术开发区关于进 一步促进产业高质量发展 1+N 政策的实施意见》的相关规定，于近日收到西藏 拉萨经济技术开发区管理委员会下发的 2022 年度产业发展扶持资金，共计 41,593,315.00 元，占公司最近一年经审计净利润的 52.63%。本次获得 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2023-41 广西梧州中恒集团股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 5 月 25 日(星期四)上午 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 5 月 18 日(星期四)至 5 月 24 日(星期三)16:00 前登 录上证路演中心网站首页点击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 （zh600252@126.com）进行提问。广西梧州中恒集团股份有限公司（以下简称 "公司"或"中恒集团"）将在业绩说明会上对投资者普遍关注的问题进行回答。 公司于 2023 年 3 月 29 日披露了《中恒集团 2022 年年度报告》，为便于广大 投资者 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 669,688,145.45, representing a year-on-year increase of 4.56%[3] - The net profit attributable to shareholders was CNY -17,116,845.17, a decrease of 119.94% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,671,103.18, down 97.78% year-on-year[3] - Basic and diluted earnings per share were both CNY -0.0050, a decline of 120.08% compared to the previous year[3] - The weighted average return on equity was -0.26%, a decrease of 1.55 percentage points[3] - The company reported significant shareholder concentration, with Guangxi Investment Group Co., Ltd. holding 859,343,587 shares, representing a substantial portion of the total shares[9] - In Q1 2023, the company reported a net profit of -29,006,693.77 CNY, a significant decline compared to a net profit of 57,322,111.10 CNY in Q1 2022, representing a year-over-year decrease of approximately 151%[23]. - The total operating profit for Q1 2023 was -31,199,103.23 CNY, compared to an operating profit of 82,321,214.09 CNY in the same period last year, indicating a drastic decline[23]. - The company’s total comprehensive income for Q1 2023 was -61,491,525.83 CNY, compared to -7,628,677.44 CNY in Q1 2022, reflecting a worsening financial position[24]. - Basic and diluted earnings per share for Q1 2023 were both -0.0050 CNY, down from 0.0249 CNY in Q1 2022[24]. - The company reported a significant loss in fair value changes amounting to -41,037,648.21 CNY in Q1 2023, compared to a gain of 7,738,692.49 CNY in Q1 2022[23]. Cash Flow and Assets - The net cash flow from operating activities increased by 241.05% to CNY 77,608,123.07[3] - The increase in cash flow from operating activities was primarily due to increased cash receipts from pharmaceutical agency business and reduced procurement activities[6] - The company's cash flow from operating activities showed a net inflow of 77,608,123.07 CNY in Q1 2023, a recovery from a net outflow of -55,021,780.87 CNY in Q1 2022[25]. - The company's cash and cash equivalents as of March 31, 2023, amounted to ¥3,580,119,678.67, slightly up from ¥3,549,889,659.07 at the end of 2022[19] - The cash and cash equivalents at the end of Q1 2023 stood at 3,528,662,178.67 CNY, an increase from 3,092,014,678.19 CNY at the end of Q1 2022[25]. - Total assets at the end of the reporting period were CNY 11,681,607,709.04, a decrease of 0.60% from the end of the previous year[3] - The total assets of the company as of March 31, 2023, were ¥11,681,607,709.04, a slight decrease from ¥11,751,848,863.82 at the end of 2022[21] - Total liabilities decreased to ¥3,449,266,781.05 in Q1 2023 from ¥3,462,470,550.07 in Q4 2022[20] Operational Changes and Strategies - The company plans to enhance its promotional efforts, which has impacted profitability in the current period[6] - The company announced that its main products, Thrombolytic Injection (Lyophilized) and Thrombolytic Injection, have had restrictions on their indications lifted, restoring their reimbursement scope to the range specified in the product instructions[11] - The company established a wholly-owned subsidiary, Zhongheng Yixin Technology Investment Co., Ltd., with an investment of RMB 500 million to enhance its technological innovation and investment management capabilities[13] - The company plans to repurchase and cancel a total of 12,944,250 restricted stock units due to unmet performance targets from its 2021 incentive plan, with repurchase prices set at RMB 1.76 and RMB 1.42 per share[15] - The company completed the cancellation of 6,373,443 shares remaining in its repurchase special securities account, with no current plans for their use[16] - The company is actively monitoring changes in national medical insurance policies that may impact its product offerings and market positioning[10] - The company has not disclosed any significant mergers or acquisitions in the recent report, focusing instead on internal growth strategies[17] - The company is committed to enhancing its market presence through strategic investments and product development initiatives[13] Cost and Expense Management - Total operating costs for Q1 2023 were ¥683,670,796.28, up 19.6% from ¥571,823,205.03 in Q1 2022[22] - Research and development expenses decreased to ¥25,174,529.19 in Q1 2023 from ¥45,658,550.65 in Q1 2022, indicating a reduction of 44.7%[22] - The net profit margin for Q1 2023 was impacted by increased operating costs, with a total profit of ¥13,869,037.33 from other income, compared to ¥11,689,913.24 in Q1 2022[22] Inventory and Receivables - Accounts receivable increased to ¥873,121,677.50 in Q1 2023 from ¥836,153,269.26 in Q4 2022, indicating a rise of 4.2%[19] - Inventory levels rose to ¥768,615,385.99 in Q1 2023, compared to ¥689,839,512.64 in Q4 2022, reflecting an increase of 11.4%[19]

Financial Performance - In 2022, the company's operating revenue was approximately ¥9.86 million, a decrease of 54.3% compared to ¥21.55 million in 2021[24]. - The company's operating revenue for 2022 was CNY 2,713,769,838.72, a decrease of 14.17% compared to CNY 3,161,843,646.17 in 2021[35]. - Net profit attributable to shareholders for 2022 was CNY 79,025,459.61, down 74.25% from CNY 306,918,694.92 in the previous year[35]. - The net cash flow from operating activities was negative CNY 170,090,446.75, compared to negative CNY 76,736,671.04 in 2021[35]. - The company's total assets at the end of 2022 were CNY 11,751,848,863.82, a decrease of 1.16% from CNY 11,889,723,464.97 at the end of 2021[35]. - The net profit for the year was CNY 12,389,674.15, a significant decrease from CNY 173,166,289.20 in the previous year, representing a decline of approximately 92.85%[108]. - The total comprehensive income for the year was CNY -83,743,394.70, compared to CNY 4,641,377.31 in the previous year, indicating a substantial decline[110]. Research and Development - The company has applied for 26 patents, including 19 invention patents, since its establishment[19]. - The company has established multiple industry-academia-research platforms, including a "Three Seven Research Center" with Shanghai University of Traditional Chinese Medicine[19]. - The company has established several national and regional research centers to enhance its R&D capabilities and core competitiveness[48]. - Laimei Pharmaceutical's R&D investment in 2022 totaled 156 million, a decrease of 27.42% year-on-year, with a capitalization ratio of 13.76%, an increase of 5.51 percentage points from the previous year[142]. - The company is focusing on the development of key products such as Esomeprazole Magnesium and Tranexamic Acid, with a significant increase in the capitalization of R&D expenses by 21.04%[142]. Product Development and Portfolio - Wuzhou Pharmaceutical has 217 product varieties and 308 drug approval numbers, including 181 traditional Chinese medicine products and 118 chemical drug formulations[18]. - Laimei Pharmaceutical's key product, Kanalin, is the first lymph tracer approved by CFDA and has won multiple industry awards, including "Outstanding Product Brand" for four consecutive years[18]. - The company has received approval for two new drug registration certificates from the National Medical Products Administration, enhancing its product portfolio[42]. - The company is focusing on the development of upgraded products such as nano carbon iron and personalized innovative medical technologies through its subsidiaries[157]. Market Strategy and Sales - The company has adopted a dual-market operation strategy, focusing on both hospital and retail markets to drive business growth[20]. - The company has implemented a sales model that combines professional academic promotion with channel distribution, enhancing market penetration[20]. - The company has expanded its online sales channels, with significant growth in sales through the Laimei Juding e-commerce platform compared to the previous period[57]. - The company plans to enhance marketing management and optimize sales channels, focusing on core product promotion capabilities and transforming sales team management[192]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Yongtuo Accounting Firm[2]. - The company’s board of directors and senior management have guaranteed the authenticity, accuracy, and completeness of the annual report[2]. - The company emphasizes that forward-looking statements in the report do not constitute substantive commitments to investors, highlighting investment risks[2]. - The company aims to strengthen the safety control of pharmaceuticals in response to the revised Drug Administration Law, ensuring compliance with regulations[95]. Investment and Financial Management - The company has ongoing research and development projects, including the injection of thrombolytic agents and various traditional Chinese medicine formulations, with several products in different stages of clinical research and registration[158]. - The total external equity investment during the reporting period was CNY 250,000, a significant decrease of 99.90% compared to CNY 25,000,000 in the previous year, indicating a strategic focus on core business operations[170]. - The company plans to shift its fund management strategy from being limited to outbound investments to also focusing on inbound fundraising, aiming to accelerate the growth of its investment projects[182]. Awards and Recognition - Laimei Pharmaceutical was recognized as a "National Technology Innovation Demonstration Enterprise" in 2019 and has been listed as a key laboratory by Chongqing Economic and Information Commission in 2021[18]. - Shuangqian Industrial has been recognized as a "Demonstration Enterprise of Intelligent Factory" in 2022, highlighting its commitment to modernization and quality[18]. - The company has received multiple awards in the Chinese chemical pharmaceutical industry, highlighting its strong market reputation and product quality[48]. Challenges and Risks - The company faced challenges in the pharmaceutical sector due to government procurement policies, impacting sales volumes across various regions[57]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, which fell by 92.99% to CNY 5,391,356.31[35]. - The gross profit margin for cardiovascular drugs in 2022 was 86.68%, down from 91.97% in 2021, indicating a decline in profitability[134].

1 证券代码：600252 证券简称：中恒集团 广西梧州中恒集团股份有限公司 投资者关系活动记录表 | --- | --- | |-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关 系活动 | 中恒集团 2021 年度业绩说明会 | | 形式 | □ 现场 √ 网上 □ 电话会议 | | 时间 | 2022 年 5 月 10 日 | | 地点 | 广西梧州 | | 上市公司 接待人员 | 中恒集团党委书记、董事长、代董事会秘书莫宏胜， | | | 常务副总经理钟敏，财务负责人易万伟，独立董事李 俊华。 2022 年 5 月 10 日，中恒集团举办了 2021 年度业 绩说明会。本次业绩说明会 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥700,487,274.79, a decrease of 10.89% compared to the same period last year[6] - The net profit attributable to shareholders for Q3 2022 was ¥37,370,863.73, down 78.71% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,047,670.21, a decline of 97.04% compared to the previous year[6] - The basic earnings per share for Q3 2022 was ¥0.0109, reflecting a decrease of 78.71% year-on-year[6] - Total operating revenue for the first three quarters of 2022 was CNY 1,890,164,817.86, a decrease of 29.1% compared to CNY 2,668,523,041.62 in the same period of 2021[36] - Net profit for the third quarter of 2022 was CNY 92,292,589.33, a significant decline of 82.4% compared to CNY 523,084,607.27 in the same quarter of 2021[38] - The company reported a total profit of CNY 135,884,567.83 for the third quarter of 2022, down 77.6% from CNY 606,001,644.95 in the same quarter of 2021[38] - The company's investment income for the first three quarters of 2022 was CNY 6,156,884.66, a decline from CNY 99,884,665.37 in the same period of 2021[38] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥11,943,764,621.64, representing a slight increase of 0.45% from the end of the previous year[8] - The equity attributable to shareholders decreased by 1.10% to ¥6,550,695,544.03 compared to the end of the previous year[8] - As of September 30, 2022, the company's total assets amounted to approximately CNY 11.94 billion, an increase from CNY 11.89 billion at the end of 2021[30] - The total liabilities increased to CNY 3.60 billion from CNY 3.20 billion, reflecting an increase of about 12.43%[34] - The company's retained earnings as of September 30, 2022, were CNY 2.44 billion, compared to CNY 2.38 billion at the end of 2021, showing an increase of approximately 2.36%[34] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥11,765,666.46, down 95.04% compared to the same period last year[6] - Cash flow from operating activities for the first three quarters of 2022 was CNY 2,051,996,633.26, a decrease of 28.0% compared to CNY 2,843,611,932.71 in 2021[40] - The net cash flow from operating activities for Q3 2022 was CNY 11,765,666.46, a significant decrease of 95% compared to CNY 237,329,231.85 in Q3 2021[42] - Total cash inflow from financing activities reached CNY 1,794,487,922.04, an increase of 51.3% from CNY 1,185,861,617.70 in the same period last year[44] - The total cash and cash equivalents at the end of Q3 2022 amounted to CNY 3,467,203,227.45, up from CNY 2,896,181,947.52 at the end of Q3 2021[44] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 134,823, with the largest shareholder holding 27.73% of the shares[12] - The company reported a total of 13,523,443 shares held in the repurchase special securities account, accounting for 0.39% of the total share capital as of September 30, 2022[17] - The top ten shareholders include Guangxi Investment Group Co., Ltd. with 963,596,802 shares, representing a significant portion of the company's equity[17] - The top ten unrestricted shareholders include several funds, with the largest being the Central Huijin Asset Management Co., Ltd. holding 49,780,800 shares[17] - The company has not disclosed any known relationships or concerted actions among the top shareholders[17] Management and Governance - The company appointed a new general manager, Ni Yidong, on July 29, 2022, with a term lasting until the end of the current board's tenure[18] - The company also appointed a new board secretary, Wang Xiangyong, on September 29, 2022, effective until the end of the current board's tenure[18] - The company appointed a new deputy general manager, Xiao Lin, on October 18, 2022, with a term until the current board's tenure ends[18] - The company continues to focus on strategic management and governance with recent appointments to enhance operational efficiency[18] - The company revised its 2021 restricted stock incentive plan to enhance its governance structure and motivate key personnel[21] Legal and Regulatory Matters - The decline in net profit was primarily attributed to national pharmaceutical policies and the impact of the pandemic, leading to a decrease in gross profit[11] - The company is facing uncertainties in drug sales due to potential changes in national policies and market conditions, which could affect future revenue[23] - The company’s subsidiary is involved in a legal dispute regarding exclusive sales rights for a product, which may impact its operational focus[25] - The company reported a court ruling requiring it to pay CNY 16.50 million in damages to Haiyue Pharmaceutical, impacting its financial outlook[28] - The company continues to monitor ongoing litigation and will fulfill its disclosure obligations to investors regarding potential risks[28] Product Development - The company received drug registration certificates for 20mg and 40mg Esomeprazole Magnesium enteric-coated capsules, enhancing its product line and market share in gastrointestinal medications[23] - The company’s subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., obtained approval for the listing application of Esomeprazole Magnesium raw materials, further expanding its product offerings[23] - The company’s subsidiary successfully passed the consistency evaluation for two specifications of Tranexamic Acid Injection, which is expected to improve market competitiveness[23] Operational Activities - The company is in the process of signing an energy-saving service contract for a rooftop photovoltaic project, with a service period of 25 years and a discount of 7.9% on the electricity price[22] - The company is actively pursuing the collection of land reserve compensation amounting to RMB 531.83228 million from the Zhaoqing High-tech Zone Land Reserve Center[24] - The company is closely monitoring the progress of its land compensation claims and is prepared to take necessary actions to protect its interests[24]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 1,189,677,543.07, a decrease of 36.80% compared to the same period last year[19]. - The net profit attributable to shareholders of the listed company was CNY 108,428,936.50, down 68.61% year-on-year[19]. - The net cash flow from operating activities was negative at CNY -59,066,966.62, a decline of 128.41% compared to the previous year[19]. - The total assets at the end of the reporting period were CNY 11,845,338,889.04, a decrease of 0.37% from the end of the previous year[19]. - The net assets attributable to shareholders of the listed company were CNY 6,546,030,531.28, down 1.17% from the previous year[19]. - Basic earnings per share for the reporting period were CNY 0.0317, a decrease of 68.55% compared to the same period last year[19]. - The weighted average return on net assets was 1.62%, a decrease of 3.30 percentage points year-on-year[19]. - The decline in operating revenue was primarily due to a decrease in pharmaceutical sales[19]. - The significant drop in net profit was attributed to decreased revenue and one-time gains from previous periods[19]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, decreased due to a larger decline in pharmaceutical revenue compared to the decrease in costs[21]. - The net cash flow from operating activities was negatively impacted by a decline in revenue and judicial freezing of some cash due to litigation, affecting the cash flow statement[21]. - Basic earnings per share changed primarily due to the variation in net profit attributable to shareholders[21]. Research and Development - R&D expenses increased by 6.62% year-on-year to CNY 68.16 million, reflecting the company's commitment to innovation[40]. - The company established multiple research centers in collaboration with universities and research institutions to enhance its R&D capabilities, including a "Three Seven Research Center" with Shanghai University of Traditional Chinese Medicine[30]. - The company is advancing its R&D projects, including traditional Chinese medicine and medical devices, with some projects reaching clinical research stages[40]. - Zhongheng Group has created several national and regional research centers, enhancing its R&D capabilities through partnerships with prestigious universities and research institutions[35]. Market Strategy and Operations - The company is focused on expanding its market presence and enhancing its research and development capabilities in the pharmaceutical sector[26]. - The company launched several new products in the personal care sector, including mouthwash, laundry detergent, and electric toothbrushes, expanding its brand influence domestically and internationally[30]. - The company is focusing on strategic procurement to reduce costs and ensure quality by establishing stable supply chains for traditional Chinese medicine materials[31]. - The company is implementing a dual sales model ("in-hospital + out-of-hospital") to mitigate the impact of COVID-19 on product sales, enhancing its market presence[31]. - The company aims to integrate its agricultural, processing, and logistics operations to create a national demonstration base for traditional Chinese medicine cultivation[30]. - The company is actively restructuring its marketing system, focusing on innovative academic promotion and enhancing its professional brand image[37]. - The company is expanding its self-operated sales team to enhance market channel management, which may increase labor and management costs[61]. Financial Position and Investments - The company increased long-term borrowings to 660,560,254.35 RMB, a rise of 258.17% from the previous year, primarily for financing purposes[46]. - The company reported a significant increase in long-term equity investments, rising by 133.75% to 312,944,850.72 RMB, due to increased investments in subsidiaries[46]. - The company has committed to invest up to 1.5 million yuan in the Xiamen Lisu Investment Partnership, representing a 37.5% stake in the partnership[50]. - The total estimated investment for the Zhongheng Pharmaceutical Intelligent Manufacturing Valley project is 432.37 million yuan, with a planned construction area of 138,415.60 square meters and a payback period of 4.65 years[52]. - The company is actively pursuing mergers and acquisitions in the healthcare sector, focusing on expanding its investment opportunities through partnerships with professional investment institutions[49]. Legal and Compliance Issues - The company faced a significant lawsuit resulting in a compensation ruling of 18,743,063.12 yuan[92]. - The company has made commitments to avoid operating in businesses that compete with its main operations to protect shareholder interests[89]. - The company has undertaken measures to ensure compliance with legal and regulatory requirements in its operations[90]. - The company has established a framework to address potential conflicts of interest with its major shareholders[89]. - The company is currently involved in an appeal process regarding a court ruling that ordered it to return 37.5 million CNY in sales rights transfer fees[96]. Environmental and Social Responsibility - The company has established a 500m³/d wastewater treatment system and seven exhaust gas treatment devices, all of which were operational in the first half of 2022[74]. - The company has developed an emergency response plan for environmental incidents and submitted it to the local ecological environment bureau[76]. - The company invested approximately CNY 12.61 million in the construction of a 3,000 mu core demonstration base for traditional Chinese medicine in the Teng County, with 1,540 mu of self-operated planting area completed and an additional 1,400 mu developed[80]. - The company has generated CNY 1.472 million in income for local farmers through land transfer of over 300 mu and has employed local farmers for planting and management work[80]. - The company supported poverty alleviation products valued at over CNY 299,000 through employee purchases and CNY 158,000 through cafeteria procurement[80]. Shareholder and Equity Information - The largest shareholder, Guangxi Investment Group, holds 963,596,802 shares, representing 27.73% of total shares[113]. - The company has a total of 36,375,000 restricted shares under the 2021 stock incentive plan, with a release schedule over the next 60 months[117]. - The management team has seen significant increases in shareholdings due to the stock incentive plan, with individual increases of 800,000 shares for several executives[118]. - The company has a total of 140,596 common stock shareholders as of the end of the reporting period[112]. - The company has not disclosed any related party relationships among the top shareholders[117]. Overall Company Outlook - The company plans to continue its market expansion and product development strategies in the upcoming quarters[165]. - The company is facing risks from industry policies and market conditions, including potential impacts from ongoing COVID-19 pandemic[58]. - The company is focusing on adjusting its business strategy to establish a differentiated competitive advantage and enhance terminal sales growth[59].

Financial Performance - The company's operating revenue for Q1 2022 was ¥640,505,143.11, a decrease of 44.54% compared to the same period last year[6] - Net profit attributable to shareholders was ¥85,822,618.97, down 52.44% year-on-year[6] - The net cash flow from operating activities was -¥55,021,780.87, representing a decline of 633.90% compared to the previous year[6] - Basic earnings per share were ¥0.0249, a decrease of 52.75% from the same period last year[6] - Total operating revenue for Q1 2022 was CNY 640,505,143.11, a decrease of 44.5% compared to CNY 1,154,801,429.41 in Q1 2021[32] - Net profit for Q1 2022 was CNY 57,322,111.10, a decline of 73.7% compared to CNY 217,859,346.06 in Q1 2021[34] - The total comprehensive income attributable to the parent company was CNY 20,872,621.78, a decrease from CNY 39,931,771.82 in the same period last year, reflecting a decline of approximately 47.8%[36] - Basic and diluted earnings per share were both CNY 0.0249, down from CNY 0.0527 in the same quarter last year, reflecting a decline of approximately 52.8%[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥11,997,417,716.07, an increase of 0.91% from the end of the previous year[8] - The total assets of Guangxi Wuzhou Zhongheng Group reached CNY 11.99 billion, an increase from CNY 11.89 billion in the previous period[26] - The company's total liabilities increased to CNY 3,315,919,320.76 in Q1 2022 from CNY 3,199,922,228.99 in Q1 2021, representing a growth of 3.6%[30] - The total liabilities decreased to CNY 6.06 billion from CNY 6.09 billion, showing a reduction of 0.5%[26] Cash Flow - Cash inflow from operating activities totaled CNY 813,405,013.30, down from CNY 1,165,571,553.59 year-over-year, representing a decrease of about 30.2%[38] - The company reported cash outflows from operating activities of CNY 868,426,794.17, compared to CNY 1,155,265,968.02 in the previous year, marking a reduction of approximately 25%[42] - Investment activities resulted in a net cash flow of CNY -146,738,652.98, a stark contrast to a positive CNY 150,252,474.02 in the same quarter last year[42] - The total cash outflow for investment activities was CNY 171,916,333.95, compared to CNY 111,418,769.41 in Q1 2021, representing an increase of approximately 54.3%[42] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 147,382[11] - The largest shareholder, Guangxi Investment Group Co., Ltd., held 27.73% of the shares, with 297,794,118 shares pledged[11] - The company reported a total of 13,523,443 shares repurchased, accounting for 0.39% of the total share capital as of March 31, 2022[15] - The company’s major shareholder, Guangxi Investment Group Co., Ltd., holds 963,596,802 shares, representing a significant portion of the total shares[15] - The company has multiple asset management plans from various funds, each holding 25,335,000 shares, indicating strong institutional interest[15] - The company’s total shareholding structure includes significant stakes from various funds, with the largest being Guangxi Investment Group Co., Ltd.[15] - The company has not disclosed any known relationships or concerted actions among its top shareholders[15] - The company’s total number of shares held by the top ten unrestricted shareholders includes significant holdings from various funds and individuals[15] Operational Changes and Developments - The decline in operating revenue was primarily due to the impact of the pandemic, medical insurance policies, and centralized procurement policies affecting sales[10] - The company reported non-recurring gains of ¥11,687,201.74 from government subsidies closely related to its normal business operations[8] - The company’s management has undergone changes, with the resignation of General Manager Jiang Shenzhou on January 16, 2022[16] - The company is actively managing its stock incentive plan, with the first grant completed on February 14, 2022[18] - Laimei Pharmaceutical's injection of methylprednisolone sodium succinate received approval for consistency evaluation in February 2022, enhancing its market position[20] - The total estimated investment for the construction of the Zhongheng Pharmaceutical Intelligent Manufacturing Valley project is approximately CNY 432.37 million, with a planned construction period of 34 months and an investment recovery period of 4.65 years[20] - The partnership agreement for the Xiamen Lisu Investment Partnership was amended, increasing the total scale from CNY 10,000 to CNY 400 million, with the company committing up to CNY 150 million[22] Research and Development - Research and development expenses for Q1 2022 were CNY 45,658,550.65, an increase of 63.7% compared to CNY 27,879,204.27 in Q1 2021[32]

Financial Performance - In 2021, the company achieved a net profit of CNY 173,166,289.20, with a net profit attributable to shareholders of CNY 306,918,694.92[8] - The company's operating revenue for 2021 was ¥3,161,843,646.17, a decrease of 14.00% compared to ¥3,676,393,702.92 in 2020[27] - Net profit attributable to shareholders for 2021 was ¥306,918,694.92, down 45.47% from ¥562,819,966.23 in 2020[27] - The basic earnings per share for 2021 was ¥0.09, a decline of 43.75% from ¥0.16 in 2020[28] - The net cash flow from operating activities for 2021 was -¥76,736,671.04, a significant decrease of 111.69% compared to ¥656,615,884.56 in 2020[27] - The company's total assets at the end of 2021 were ¥11,889,723,464.97, a slight decrease of 0.71% from ¥11,974,613,830.64 at the end of 2020[27] - The weighted average return on equity for 2021 was 4.60%, down 3.90 percentage points from 8.50% in 2020[30] - The company reported a net profit attributable to shareholders of -¥213,971,169.29 in Q4 2021, indicating a significant loss in that quarter[31] Dividend and Profit Distribution - The company proposed a cash dividend of CNY 0.27 per 10 shares, totaling CNY 92,480,635.01 to be distributed to shareholders[8] - The actual distributable profit for 2021 was CNY 2,380,086,278.25, while the parent company's distributable profit was CNY 1,717,413,660.30[8] - The company has committed to distributing over 30% of its net profit to shareholders annually, with a cash dividend ratio exceeding 52% for the year 2020[41] Operational Risks and Compliance - The company did not face any significant operational risks during the reporting period[12] - The company has no non-operating fund occupation by controlling shareholders or related parties[11] - The company has no violations in decision-making procedures for external guarantees[11] - The audit report issued by Yongtuo Accounting Firm confirmed the financial report's authenticity and completeness[7] - The board of directors and supervisory board members confirmed the accuracy and completeness of the annual report[6] Research and Development - The company has collaborated with 23 research institutions on 43 R&D projects, achieving significant breakthroughs in various pharmaceutical innovations[41] - Research and development expenses increased by 50.29% to CNY 197.66 million, reflecting the company's commitment to enhancing core competitiveness[55] - The total R&D investment amounted to CNY 215,436,698.50, accounting for 6.81% of operating revenue, with capitalized R&D investment making up 8.25%[73] - The company is focusing on clinical evidence-based medicine in its marketing strategies to adapt to regulatory changes and market demands[128] Product Development and Market Strategy - The company launched new products such as mixed grain turtle jelly and double money snail powder, collaborating with celebrities for promotional activities[41] - The company aims to enhance its brand influence and optimize product structure by actively participating in the procurement of traditional Chinese medicine[39] - The company plans to focus on strategic development in cardiovascular, anti-tumor, digestive, anti-infection, and orthopedic fields, actively introducing new products and technologies[50] - The company is expanding its hospital business by optimizing commercial channel structures and enhancing its marketing system to drive sales growth[151] Market Position and Recognition - In 2021, the company ranked 19th in the "Top 100 Chinese Pharmaceutical Enterprises" and 79th in the "Top 100 Chinese Pharmaceutical Industry" rankings, indicating strong brand recognition and market position[44] - The company’s product "Thrombolytic Injection" is a core product for cardiovascular diseases, while "Chinese Herbal Medicine" has been recognized as a national invention patent product[45] Strategic Investments and Acquisitions - The company plans to invest between RMB 200 million and RMB 300 million in Guohai Securities' private placement, pending regulatory approval[132] - The company has established the Guangxi Lihua Zhongheng Pharmaceutical Investment Partnership with a total scale of RMB 300 million, with the company contributing RMB 297 million[132] - The company is pursuing strategic investments and acquisitions to establish new growth points and expand its project portfolio[151] Corporate Governance and Management - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 12.2282 million yuan (pre-tax)[180] - The company has experienced changes in its board and management personnel due to job relocations and appointments[181] - The company ensures compliance with tax regulations when distributing remuneration and allowances[180] Future Outlook and Challenges - The company aims to become one of the top 50 pharmaceutical companies in China and top 10 in traditional Chinese medicine by the end of 2025[148] - The company is facing risks from industry policies and market changes, including the impact of national medical reform and ongoing COVID-19 pandemic challenges[152] - The company plans to enhance its research on the safety and efficacy of its flagship products, particularly the thrombolytic agent, to support clinical use with robust data[89]

Financial Performance - The company's operating revenue for Q3 2021 was ¥786,074,681.45, a decrease of 33.31% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2021 was ¥175,506,167.50, an increase of 59.89% year-on-year[5] - The net profit after deducting non-recurring gains and losses for Q3 2021 was ¥102,875,008.18, up 17.41% from the previous year[5] - The basic earnings per share for Q3 2021 was ¥0.0512, reflecting a growth of 60.00% compared to the same period last year[5] - Total operating revenue for the first three quarters of 2021 was CNY 2,668,523,041.62, a decrease of 8.8% compared to CNY 2,925,829,236.51 in the same period of 2020[48] - Operating profit for the first three quarters of 2021 was CNY 512,054,886.54, down from CNY 540,681,835.25 in 2020, reflecting a decline of 5.3%[48] - Net profit attributable to shareholders of the parent company for the first three quarters of 2021 was CNY 520,889,864.21, compared to CNY 428,122,883.31 in 2020, representing an increase of 21.6%[50] - The total comprehensive income for the first three quarters of 2021 was CNY 385,046,066.85, compared to CNY 490,303,041.58 in 2020, indicating a decrease of 21.5%[50] - The company reported a net profit of CNY 523,084,607.27 for the first three quarters of 2021, compared to CNY 435,854,813.00 in 2020, an increase of 20.0%[49] Assets and Liabilities - Total assets at the end of the reporting period were ¥11,691,903,042.61, a decrease of 2.36% from the end of the previous year[7] - As of September 30, 2021, the company's total assets amounted to CNY 11.69 billion, a decrease from CNY 11.97 billion as of December 31, 2020, reflecting a decline of approximately 2.4%[42] - The company's cash and cash equivalents decreased to CNY 2.92 billion from CNY 3.56 billion, representing a decline of about 18.1% year-over-year[42] - The company's total current liabilities decreased to CNY 2.43 billion from CNY 3.11 billion, a reduction of about 21.8%[44] - Total liabilities decreased to CNY 2,877,214,992.03 in Q3 2021 from CNY 3,746,860,903.35 in Q3 2020, a reduction of 23.2%[48] - The total current liabilities were approximately ¥3.11 billion, a decrease of ¥2.49 million compared to the previous period[59] - Non-current liabilities totaled approximately ¥635.67 million, a decrease of ¥6.11 million compared to the previous period[59] Shareholder Information - The company reported a total equity attributable to shareholders of ¥6,860,946,273.93, a slight increase of 0.17% from the previous year[7] - The company reported a total of 963,596,802 shares held by major shareholders, with the largest being Guangxi Investment Group Co., Ltd. holding 963,596,802 shares[18] - The top ten shareholders collectively hold 49,898,443 shares, accounting for 1.44% of the total share capital, which is intended for equity incentive implementation[19] - The company has initiated a restricted stock incentive plan, proposing to grant up to 49,898,443 shares, with an initial grant of 43,080,000 shares to 250 individuals[20] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥237,329,231.85, down 48.08% year-on-year[5] - Cash inflow from operating activities for the first three quarters of 2021 was CNY 3,429,308,266.63, a decrease of 1.87% compared to CNY 3,494,859,800.38 in the same period of 2020[52] - Net cash flow from operating activities decreased to CNY 237,329,231.85 from CNY 457,139,835.03, representing a decline of 48.1% year-over-year[52] - Cash inflow from financing activities totaled CNY 1,185,861,617.70, down from CNY 1,612,400,669.46 in 2020, a decrease of 26.4%[54] - Net cash flow from financing activities was negative at CNY -703,604,148.46, compared to a positive CNY 683,996,785.01 in the previous year[54] Investments and Projects - The company plans to invest up to RMB 400 million in the Xiamen Lisu Investment Partnership, with a maximum contribution of RMB 150 million from the company itself[25] - The company has completed the first phase of capital contribution of RMB 100 million to the health entrepreneurship fund, with the company contributing RMB 40 million, representing 40% of the total[30] - The company has established a partnership with Guohai Innovation Capital to set up the health entrepreneurship fund, with the company holding an 80% stake[28] - The company has successfully completed the private placement fund registration for the health entrepreneurship fund, which has a total planned scale of RMB 300 million[28] Legal Matters - The company is involved in a lawsuit regarding the transfer of its wholly-owned subsidiary's equity, with the case still pending a final judgment[35] - The company received an execution payment of CNY 1.32 million during the reporting period, indicating progress in legal proceedings[37] - The company successfully resolved a lawsuit with no liability through mediation, concluding the case without any financial impact[38] Research and Development - Research and development expenses increased significantly to CNY 99,706,021.49 in 2021 from CNY 41,452,705.18 in 2020, marking an increase of 140.0%[48]